Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-year extension study of secukinumab in active psoriatic arthritis
2013-001241-13Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of secukinumab in psoriatic arthritis (PsA) (2 arms), sponsored by Novartis. Started Jul 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2013-001241-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001241-13.